scholarly journals The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics

2019 ◽  
Vol 69 (5) ◽  
pp. 877-883 ◽  
Author(s):  
Johan Vekemans ◽  
Fernando Gouvea-Reis ◽  
Jerome H Kim ◽  
Jean-Louis Excler ◽  
Pierre R Smeesters ◽  
...  
Keyword(s):  
Research And Development ◽  
World Health Organization ◽  
Vaccine Efficacy ◽  
Group A Streptococcus ◽  
World Health ◽  
Product Characteristics ◽  
Technology Roadmap ◽  
Development Technology ◽  
Group A ◽  
Health Organization

Abstract Group A Streptococcus (GAS) infections result in a considerable underappreciated burden of acute and chronic disease globally. A 2018 World Health Assembly resolution calls for better control and prevention. Providing guidance on global health research needs is an important World Health Organization (WHO) activity, influencing prioritization of investments. Here, the role, status, and directions in GAS vaccines research are discussed. WHO preferred product characteristics and a research and development technology roadmap, briefly presented, offer an actionable framework for vaccine development to regulatory and policy decision making, availability, and use. GAS vaccines should be considered for global prevention of the range of clinical manifestations and associated antibiotic use. Impediments related to antigen diversity, safety concerns, and the difficulty to establish vaccine efficacy against rheumatic heart disease are discussed. Demonstration of vaccine efficacy against pharyngitis and skin infections constitutes a key near-term strategic goal. Investments and collaborative partnerships to diversify and advance vaccine candidates are needed.

scholarly journals Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017

Vaccine ◽  
2019 ◽  
Vol 37 (50) ◽  
pp. 7408-7418 ◽  
Author(s):  
Sami L. Gottlieb ◽  
Birgitte K. Giersing ◽  
Julian Hickling ◽  
Rebecca Jones ◽  
Carolyn Deal ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
World Health Organization ◽  
World Health ◽  
Meeting Report ◽  
Product Characteristics ◽  
Health Organization ◽  
Simplex Virus

scholarly journals On the Delta Plus Variant of SARS-CoV-2

2021 ◽  
Vol 3 (6) ◽  
pp. 52-55
Author(s):  
Selia Chowdhury ◽  
Mehedi Hasan Bappy
Keyword(s):  
Public Health ◽  
World Health Organization ◽  
Vaccine Efficacy ◽  
World Health ◽  
Future Research ◽  
Current Trends ◽  
The World ◽  
Associated Symptoms ◽  
Health Organization

The unprecedented consequences brought by the COVID pandemic are still going on, the virus hasn’t been tamed yet. It is evolving through mutations to consistently being a risk to public health. Recently, the Delta variant has been declared as the variant of concern by the World Health Organization (WHO). In this article, a subvariant of Delta known as Delta Plus has been presented to provide a relevant foundation for future research works. The evolution, pathogenesis, associated symptoms, suggested prevention and treatments, vaccine efficacy, and current trends of transmission of Delta Plus variant of SARS-CoV-2 are reviewed and discussed.

World Health Organization

1953 ◽  
Vol 7 (1) ◽  
pp. 149-151 ◽  
Keyword(s):  
World Health Organization ◽  
World Health ◽  
Laboratory Work ◽  
International Group ◽  
The World ◽  
Regional Conference ◽  
Group A ◽  
Laboratory Procedures ◽  
Health Organization ◽  
Individual Training

The World Health Organization sponsored an inter-regional conference on rabies, held on Coonoor, India, during July 1952, which gave intensive and individual training in complicated laboratory procedures to an international group. A consultant staff of eight members gave lectures, led discussions, and supervised the laboratory work of 47 participants. One of die objects of die conference was to teach standardized procedures in rabies tests so that results obtained in laboratories diroughout the world might be compared.

scholarly journals Saliva-Based ELISAs for Effective SARS-CoV-2 Antibody Monitoring in Vaccinated Individuals

2021 ◽  
Vol 12 ◽  
Author(s):  
Joseph G. Casian ◽  
Aaron N. Angel ◽  
Ronell Lopez ◽  
Cedie Bagos ◽  
Melanie A. MacMullan ◽  
...  
Keyword(s):  
Immune Response ◽  
Global Health ◽  
World Health Organization ◽  
Vaccine Efficacy ◽  
World Health ◽  
Antibody Detection ◽  
Serological Testing ◽  
The World ◽  
Immunosorbent Assays ◽  
Health Organization

In March 2020, the World Health Organization (WHO) declared a global health emergency—the coronavirus disease 2019 (COVID-19) pandemic. Since then, the development and implementation of vaccines against the virus amidst emerging cases of re-infection has prompted researchers to work towards understanding how immunity develops and is sustained. Serological testing has been instrumental in monitoring the development and persistence of antibodies against SARS-CoV-2 infection, however inconsistencies in detection have been reported by different methods. As serological testing becomes more commonplace, it is important to establish widespread and repeatable processes for monitoring vaccine efficacy. Therefore, we present enzyme linked immunosorbent assays (ELISAs) compatible for antibody detection in saliva as highly accurate, efficacious, and scalable tools for studying the immune response in individuals vaccinated against SARS-CoV-2.

Sign in / Sign up

Export Citation Format

Share Document